Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock

36.43  +0.23 (+0.64%)

After market: 36.999 +0.57 (+1.56%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to EXEL. EXEL was compared to 572 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. EXEL is evaluated to be cheap and growing strongly. This does not happen too often! This makes EXEL very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year EXEL was profitable.
EXEL had a positive operating cash flow in the past year.
EXEL had positive earnings in each of the past 5 years.
Each year in the past 5 years EXEL had a positive operating cash flow.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

1.2 Ratios

EXEL has a Return On Assets of 15.77%. This is amongst the best in the industry. EXEL outperforms 98.05% of its industry peers.
EXEL's Return On Equity of 20.52% is amongst the best of the industry. EXEL outperforms 97.17% of its industry peers.
The Return On Invested Capital of EXEL (18.78%) is better than 97.70% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EXEL is significantly below the industry average of 13.83%.
The last Return On Invested Capital (18.78%) for EXEL is above the 3 year average (7.03%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 15.77%
ROE 20.52%
ROIC 18.78%
ROA(3y)7.28%
ROA(5y)8.82%
ROE(3y)8.99%
ROE(5y)10.39%
ROIC(3y)7.03%
ROIC(5y)8.48%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 100 150

1.3 Margins

EXEL has a better Profit Margin (22.43%) than 97.35% of its industry peers.
EXEL's Profit Margin has declined in the last couple of years.
EXEL has a better Operating Margin (29.22%) than 98.41% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
EXEL's Gross Margin of 96.25% is amongst the best of the industry. EXEL outperforms 96.64% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.22%
PM (TTM) 22.43%
GM 96.25%
OM growth 3Y-5.74%
OM growth 5Y-28.9%
PM growth 3Y0.09%
PM growth 5Y-32.47%
GM growth 3Y-0.1%
GM growth 5Y-0.18%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

EXEL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
EXEL has less shares outstanding than it did 1 year ago.
EXEL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

2.2 Solvency

EXEL has an Altman-Z score of 10.92. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
EXEL's Altman-Z score of 10.92 is amongst the best of the industry. EXEL outperforms 86.55% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.92
ROIC/WACC1.69
WACC11.11%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.93 indicates that EXEL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.93, EXEL is in line with its industry, outperforming 45.66% of the companies in the same industry.
EXEL has a Quick Ratio of 3.88. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.88, EXEL is in line with its industry, outperforming 47.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.88
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 485.71% over the past year.
EXEL shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.85% yearly.
Looking at the last year, EXEL shows a quite strong growth in Revenue. The Revenue has grown by 17.31% in the last year.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 16.47% on average per year.
EPS 1Y (TTM)485.71%
EPS 3Y22.28%
EPS 5Y-14.85%
EPS Q2Q%N/A
Revenue 1Y (TTM)17.31%
Revenue growth 3Y22.83%
Revenue growth 5Y16.47%
Sales Q2Q%14.33%

3.2 Future

The Earnings Per Share is expected to grow by 43.78% on average over the next years. This is a very strong growth
EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.43% yearly.
EPS Next Y171.46%
EPS Next 2Y64.46%
EPS Next 3Y52.33%
EPS Next 5Y43.78%
Revenue Next Year17.97%
Revenue Next 2Y9.13%
Revenue Next 3Y9.9%
Revenue Next 5Y11.43%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 22.21, the valuation of EXEL can be described as rather expensive.
Compared to the rest of the industry, the Price/Earnings ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.40% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of EXEL to the average of the S&P500 Index (28.29), we can say EXEL is valued slightly cheaper.
A Price/Forward Earnings ratio of 21.05 indicates a rather expensive valuation of EXEL.
Based on the Price/Forward Earnings ratio, EXEL is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
EXEL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.21
Fwd PE 21.05
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 96.81% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 95.75% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 24.05
EV/EBITDA 13.03
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
EXEL's earnings are expected to grow with 52.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y64.46%
EPS Next 3Y52.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (1/21/2025, 8:00:02 PM)

After market: 36.999 +0.57 (+1.56%)

36.43

+0.23 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2024-10-29/amc
Earnings (Next)02-11 2025-02-11/amc
Inst Owners87.56%
Inst Owner Change-0.14%
Ins Owners1.67%
Ins Owner Change1.13%
Market Cap10.40B
Analysts76.55
Price Target33.71 (-7.47%)
Short Float %3.72%
Short Ratio4.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.17%
Min EPS beat(2)13.37%
Max EPS beat(2)148.98%
EPS beat(4)3
Avg EPS beat(4)42.3%
Min EPS beat(4)-17.73%
Max EPS beat(4)148.98%
EPS beat(8)5
Avg EPS beat(8)16.27%
EPS beat(12)9
Avg EPS beat(12)48.02%
EPS beat(16)11
Avg EPS beat(16)56.12%
Revenue beat(2)2
Avg Revenue beat(2)21.14%
Min Revenue beat(2)7.95%
Max Revenue beat(2)34.34%
Revenue beat(4)2
Avg Revenue beat(4)7.68%
Min Revenue beat(4)-9.49%
Max Revenue beat(4)34.34%
Revenue beat(8)3
Avg Revenue beat(8)3.26%
Revenue beat(12)6
Avg Revenue beat(12)4.21%
Revenue beat(16)8
Avg Revenue beat(16)4.38%
PT rev (1m)1.17%
PT rev (3m)19.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.07%
EPS NY rev (1m)0%
EPS NY rev (3m)8.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)17.67%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)5.5%
Valuation
Industry RankSector Rank
PE 22.21
Fwd PE 21.05
P/S 5
P/FCF 24.05
P/OCF 22.12
P/B 4.57
P/tB 4.7
EV/EBITDA 13.03
EPS(TTM)1.64
EY4.5%
EPS(NY)1.73
Fwd EY4.75%
FCF(TTM)1.51
FCFY4.16%
OCF(TTM)1.65
OCFY4.52%
SpS7.29
BVpS7.97
TBVpS7.74
PEG (NY)0.13
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.77%
ROE 20.52%
ROCE 23.71%
ROIC 18.78%
ROICexc 35%
ROICexgc 36.7%
OM 29.22%
PM (TTM) 22.43%
GM 96.25%
FCFM 20.78%
ROA(3y)7.28%
ROA(5y)8.82%
ROE(3y)8.99%
ROE(5y)10.39%
ROIC(3y)7.03%
ROIC(5y)8.48%
ROICexc(3y)15.94%
ROICexc(5y)18.54%
ROICexgc(3y)17.03%
ROICexgc(5y)19.93%
ROCE(3y)8.87%
ROCE(5y)10.7%
ROICexcg growth 3Y-11.62%
ROICexcg growth 5Y-31.91%
ROICexc growth 3Y-10.13%
ROICexc growth 5Y-31.01%
OM growth 3Y-5.74%
OM growth 5Y-28.9%
PM growth 3Y0.09%
PM growth 5Y-32.47%
GM growth 3Y-0.1%
GM growth 5Y-0.18%
F-Score9
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 135.95%
Cap/Sales 1.81%
Interest Coverage 250
Cash Conversion 73.94%
Profit Quality 92.65%
Current Ratio 3.93
Quick Ratio 3.88
Altman-Z 10.92
F-Score9
WACC11.11%
ROIC/WACC1.69
Cap/Depr(3y)253.99%
Cap/Depr(5y)249.83%
Cap/Sales(3y)2.8%
Cap/Sales(5y)2.56%
Profit Quality(3y)156.77%
Profit Quality(5y)158.07%
High Growth Momentum
Growth
EPS 1Y (TTM)485.71%
EPS 3Y22.28%
EPS 5Y-14.85%
EPS Q2Q%N/A
EPS Next Y171.46%
EPS Next 2Y64.46%
EPS Next 3Y52.33%
EPS Next 5Y43.78%
Revenue 1Y (TTM)17.31%
Revenue growth 3Y22.83%
Revenue growth 5Y16.47%
Sales Q2Q%14.33%
Revenue Next Year17.97%
Revenue Next 2Y9.13%
Revenue Next 3Y9.9%
Revenue Next 5Y11.43%
EBIT growth 1Y1383.6%
EBIT growth 3Y15.78%
EBIT growth 5Y-17.19%
EBIT Next Year257.24%
EBIT Next 3Y64.84%
EBIT Next 5Y27.68%
FCF growth 1Y25.98%
FCF growth 3Y17.9%
FCF growth 5Y-5.2%
OCF growth 1Y22.04%
OCF growth 3Y16.84%
OCF growth 5Y-4.32%